LLY vs NVS
ELI Lilly & Co. and Novartis AG, side by side — 10 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | LLY | NVS |
|---|---|---|
| Revenue | $65.2B | $54.5B |
| Net income | $20.6B | $14.0B |
| Gross margin | 83.0% | 78.8% |
| Net margin | 31.7% | 25.6% |
| Return on equity | 101.2% | 31.0% |
| Diluted EPS | $22.95 | $7.15 |
| Dividend / share | $6.23 | · |
| Payout ratio | 26.1% | · |
| Free cash flow | · | $17.6B |
| Equity | $26.5B | $46.1B |
| Net debt / equity | 1.33× | 0.37× |
| Current ratio | 1.58× | 1.12× |
| Revenue CAGR 5y | 21.6% | 2.3% |
| Profit CAGR 5y | 27.2% | 11.6% |
LLY bills 1.2× the revenue of NVS, and keeps more of each dollar of revenue as profit (31.7% against 25.6%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
10 years side by side
| Fiscal year | LLY | NVS |
|---|---|---|
| FY2025 | $65.2B | $54.5B |
| FY2024 | $45.0B | $50.3B |
| FY2023 | $34.1B | $45.4B |
| FY2022 | $28.5B | $42.2B |
| FY2021 | $28.3B | $42.8B |
| FY2020 | $24.5B | $48.7B |
| FY2019 | $22.3B | $47.5B |
| FY2018 | $21.5B | $44.8B |
| FY2017 | $20.0B | $42.4B |
| FY2016 | $21.2B | $48.5B |
Bottom line
| Fiscal year | LLY | NVS |
|---|---|---|
| FY2025 | $20.6B | $14.0B |
| FY2024 | $10.6B | $11.9B |
| FY2023 | $5.2B | $14.8B |
| FY2022 | $6.2B | $7.0B |
| FY2021 | $5.6B | $24.0B |
| FY2020 | $6.2B | $8.1B |
| FY2019 | $8.3B | $11.7B |
| FY2018 | $3.2B | $12.6B |
| FY2017 | $-204.1M | $7.7B |
| FY2016 | $2.7B | $6.7B |
10 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +$10,647,000,000 | LLY |
| FY2024 | −$5,274,000,000 | NVS |
| FY2023 | −$11,316,000,000 | NVS |
| FY2022 | −$13,664,600,000 | NVS |
| FY2021 | −$14,462,600,000 | NVS |
| FY2020 | −$24,119,200,000 | NVS |
| FY2019 | −$25,178,500,000 | NVS |
| FY2018 | −$23,339,700,000 | NVS |
| FY2017 | −$22,407,200,000 | NVS |
| FY2016 | −$27,295,900,000 | NVS |
The higher-revenue side has changed between LLY and NVS over this period. The gap has narrowed since the earliest year compared.
10 of 19 comparable fiscal years — a year missing data on either side is not counted.
10 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +6.1 pp | LLY |
| FY2024 | −0.2 pp | NVS |
| FY2023 | −17.3 pp | NVS |
| FY2022 | +5.4 pp | LLY |
| FY2021 | −36.4 pp | NVS |
| FY2020 | +8.7 pp | LLY |
| FY2019 | +12.6 pp | LLY |
| FY2018 | −13.1 pp | NVS |
| FY2017 | −19.2 pp | NVS |
| FY2016 | −0.9 pp | NVS |
The higher net margin has changed hands between LLY and NVS over this period.
10 of 19 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
NVS's net margin has been more volatile than LLY's over the 10 comparable fiscal years — 11.6 percentage points of standard deviation against 10.1.
10 of 19 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in net margin changed hands between LLY and NVS over these 10 fiscal years — LLY led in 4 and NVS in 6.
10 of 19 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
LLY's return on equity has been more volatile than NVS's over the 10 comparable fiscal years — 46.4 percentage points of standard deviation against 9.6.
10 of 18 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in return on equity changed hands between LLY and NVS over these 10 fiscal years — LLY led in 9 and NVS in 1.
10 of 18 comparable fiscal years — a year missing data on either side is not counted.